Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Avelumab
Brand Name Bavencio®
Payment Category Medicare Part B
Year Introduced 2017
Type of Drug PD-L1 blocking antibody
Manufacturer Pfizer, EMD Serono, Inc
Medical Affairs Questions (date verified) 800.438.1985
Coverage & Reimbursement Questions 844.826.8371
HCPCS J9023
Billing Unit 10 mg
Medicare Payment Limit (Effective January 1, 2021) $85.33

FDA-Approved Indication(s)

  • Indicated for the treatment of 1) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma; 2a) maintenance treatment of patients with locally advanced or metastatic urothelial cancer (UC) that has not progressed with first-line platinum-containing chemotherapy, b) patients with locally advanced or metastatic UC who have disease progression following a platinum-containing chemotherapy, or c)patients with locally advanced or metastatic UC whohave disease progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; and 3) first-line treatment, in combination with axitinib, of patients with advanced renal cell carcinoma. (6/30/20)

Approved Indication(s) with Orphan Drug Status Merkel cell carcinoma
ICD-10 Code(s) for Labeled Indication(s) Merkel cell carcinoma [C4A.xx]; Malignant neoplasm of ureter [C66.x]; Malignant neoplasm of bladder [C67.x]; Malignant neoplasm of other and unspecified urinary organs [C68.x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US